

REMS Document
Initial Approval 12/2013

NDA 203469

Iclusig[®] (ponatinib) tablets
Drug Class: Tyrosine Kinase Inhibitor

ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, MA 02139
Phone: (617) 494-0400
Fax: (617) 225-2688

Risk Evaluation and Mitigation Strategy (REMS)

I. GOALS

The goals of the Iclusig REMS are to:

- Inform prescribers of the indications for Iclusig which are limited to:
 - Treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
 - Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated.
- Inform prescribers of the serious risk of vascular occlusion and thromboembolism associated with Iclusig treatment.

II. REMS ELEMENTS

A. Communication Plan

ARIAD will implement the following communication plan for Healthcare Providers who are likely to prescribe Iclusig. This communication plan will consist of the following:

1. **REMS Letter** - *REMS Letter to Healthcare Providers* will be sent within 21 days after the REMS approval date, and will be distributed electronically or by mail to hematologists and oncologists and to other Healthcare Providers known or likely to be Iclusig prescribers. If a targeted Healthcare Provider's email address is not available, or if an email is undeliverable, the provider will receive the letter through the mail. The *REMS Letter to Healthcare Providers* will inform Healthcare Providers of the approved indications for Iclusig and the serious risk of vascular occlusion and thromboembolism associated with Iclusig. The letter will be accompanied by the

Prescribing Information (PI) and the *Iclusig REMS Fact Sheet*. The letter will be available from the *Iclusig REMS Website* (www.IclusigREMS.com) at the time of distribution and will remain on the website for the duration of the REMS.

2. REMS Letter for Professional Societies - A *REMS Letter for Professional Societies* will be distributed within 21 days after the REMS approval date. The letter will be distributed electronically or by mail. The *REMS Letter for Professional Societies* will inform the leadership of the professional societies described below of the approved indications for Iclusig and of the serious risk of vascular occlusion and thromboembolism associated with Iclusig. The leadership of the professional societies will be asked to distribute this information to their memberships.

The *REMS Letters for Professional Societies* will be distributed to the following organizations:

- American Society of Clinical Oncology (ASCO)
- American Society of Hematology (ASH)
- Oncology Nursing Society (ONS)
- National Comprehensive Cancer Network (NCCN)
- Hematology Oncology Pharmacy Association (HOPA)
- American Pharmacists Association (APhA)
- American Society of Health-System Pharmacists (ASHP)

The letter will be sent to MedWatch at the same time it is sent to the Professional Societies.

3. REMS Fact Sheet - An *Iclusig REMS Fact Sheet* will be available for Healthcare Providers. The *Iclusig REMS Fact Sheet* will be included in the mailings of the *REMS Letter to Healthcare Providers* and the *REMS Letter for Professional Societies* and will be available on the Iclusig REMS website (www.IclusigREMS.com). Hard copies of the *Iclusig REMS Fact Sheet* will also be distributed by ARIAD's sales representatives and medical field-based personnel to Healthcare Providers during follow-up details/visits with Healthcare Providers for the first 12 months after the approval of the Iclusig REMS.

4. Journal Information Piece - ARIAD will publish in the following professional journals an *information piece* that includes the approved indications for Iclusig and the serious risk of vascular occlusion and thromboembolism associated with Iclusig:

- Journal of Clinical Oncology
- Blood
- New England Journal of Medicine
- Hematology Oncology
- US Oncology & Hematology

The information piece will be published quarterly in each publication for one year following the REMS approval.

5. Scientific Meetings - The *Iclusig REMS Fact Sheet* and the Prescribing Information, will be prominently displayed at scientific meetings where ARIAD has a presence (e.g., booth) for one year following the REMS approval.

6. Iclusig REMS Website - The *Iclusig REMS Website* will be available within 15 days after the REMS approval date. The website (www.IclusigREMS.com) will contain information on the Iclusig REMS and will provide access to all the REMS materials, and the US Prescribing Information. The website will be available for the duration of the REMS.

The following are part of the REMS and are appended.

- The *REMS Letter to Healthcare Providers* (print and email version)
- The *REMS Letter for Professional Societies* (print and email version)
- The *REMS Fact Sheet*
- The *Journal Information Piece*
- The *Iclusig REMS Website* (Landing Page)

B. Timetable for Submission of Assessments

ARIAD will submit REMS assessments to FDA 1 year, 3 years and 7 years from the date of initial approval of the REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment will conclude no earlier than 60 days before the submission date for that assessment. ARIAD will submit each assessment so that it will be received by the FDA on or before the due date.